



Saturday, December 10, 2022

Oral Presentations at ASH Annual Meeting

Note: All times listed are Central Time

Presentation	Speaker	Time/Location
109: Single-Cell RNA-Seq Reveals an Interferon-Driven Inflammatory CD4 Naïve T Cell Subpopulation at Day 100 in Hematopoietic Stem Cell Transplant Patients That Ultimately Develop Chronic GVHD	Alexandre Albanese, PhD, Dana-Farber/Boston Children's	9:30 am 252-254
43 Epigenetic Resistance to Menin-MLL1 Inhibition Is Driven By Loss of the Non-Canonical Polycomb Repressive Complex 1.1 in NUP98-Rearranged AML	Emily B. Heikamp, MD, PhD, Dana-Farber/Boston Children's	9:30 am 343-345
122: Epitope Engineered Hematopoietic Stem and Progenitor Cells to Enable CAR-T Cell Immunotherapy for Acute Myeloid Leukemia	Gabriele Casirati, MD, Dana-Farber/Boston Children's	9:45 am Great Hall B/C
111: Early Breakthrough T Cell Proliferation Despite CNI/MTX Prophylaxis Is a Harbinger of Acute GVHD (aGVHD) and Is Controlled by Abatacept: Mechanism of Success of the ABA2 aGVHD Prevention Trial	Alexandre Albanese, PhD, Dana-Farber/Boston Children's	10:00 am 252-254
102: Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology	Junko Tsuji, PhD	10:45 am R06-R09
108: Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy	Romanos Sklavenitis-Pistofidis, MD	10:45 am R02-R05
134: COVID-19 Is Associated with an Increased Risk of Venous Thromboembolism, but Not Arterial Ischemic Stroke in Hospitalized Children: A Multicenter Observational Study	Riten Kumar, MD, MSc, Dana-Farber/Boston Children's	12:15 pm Great Hall A/D
165: Targeting CNS Lymphoma with Intravenous Axicabtagene CiloleuceL: Evidence for Transcriptional Evolution Towards a Prominent Interferon Signature in CAR-T Cells Trafficking to the Tumor Site	Ulrike Gerdemann, MD, Dana-Farber/Boston Children's	12:30 pm La Nouvelle Orleans Ballroom AB
148: Genome-Wide CRISPR-Cas9 Screen Identifies KDM6A as a Modulator of Daratumumab Sensitivity in Multiple Myeloma	Jiye Liu, PhD	12:45 pm 288-290



Saturday, December 10, 2022

Scientific Program: Overcoming T-cell Burnout and Exhaustion	Leslie S. Kean, MD, PhD, Dana-Farber/Boston Children's Hospital, Chair	2:00 - 3:15 pm 271-273
Special Scientific Symposia: Fundamentals of NK Cell Biology	Rizwan Romee, MD	2:00 - 3:15 pm 293-294
247: Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies	Paul G. Richardson, MD	2:00 pm R02-R05
241: BRD9 Is Essential for Ribosome Biogenesis and the Survival of Multiple Myeloma Cells	Keiji Kurata, MD, PhD	2:00 pm R06-R09
231: Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia	Jorge J. Castillo, MD	2:30 pm New Orleans Theater C
207: Combinatorial Effects of BH3 Mimetics and CAR T Cells Targeting T-Cell Lymphomas	Tayla B. Heavican-Foral, PhD	2:30 pm 388-390
244: Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation	Elizabeth D. Lightbody, PhD	2:45 pm R06-R09
Scientific Program: Platelet Transfusion Outcomes in the Preterm Infant – The Intersection Between Hemostatic Efficacy and Immune/Inflammatory Modulation of Platelets	Martha Sola-Visner, MD, Boston Children's	4:00 - 5:35 pm 252-254
Scientific Program: Seed and Soil: The Role of Inflammation in Myeloid Malignancy	Kimberly Stegmaier, Dana-Farber/Boston Children's, Chair	4:00 - 5:35 pm R02-R05
289: Eltrombopag in Pediatric Patients with Previously Untreated or Refractory/Relapsed Severe Aplastic Anemia: The Phase II Escalate Trial	Akiko Shimamura, MD, PhD, Dana-Farber/Boston Children's	4:00 pm 260-262
350: PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy via Promoting Immunosuppressive Microenvironment	Tengteng Yu, MD	4:15 pm New Orleans Theater C
344: Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease	Christine E. Ryan, MD	4:15 pm R06-R09
369: Late Graft Failure in MDS and Acute Leukemia Patients Receiving Allogenic	Cindy Lynn Hickey, MD, FRCPC	4:30 pm 343-345



Saturday, December 10, 2022

Hematopoietic Cell Transplantation with Post
Transplant Cyclophosphamide as GVHD
Prophylaxis

381: Access and Treatment Equity Across the Comprehensive Cancer Center Catchment Area: Targets for Disparities Remediation in Acute Leukemia Research Participation	Andrew Hantel, MD	4:30 pm 208-210
---	-------------------	--------------------

359: A Novel Human OX40L-CAR-Treg Specifically Targets Activated Antigen- Presenting Cells and Effectively Controls T Cell Alloreactivity and Xeno-GvHD	Xianliang Rui, PhD, Dana-Farber/Boston Children's	5:00 pm 393-396
--	--	--------------------

377: Maintenance Therapy with Venetoclax/Azacitidine Can Be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study	Jacqueline S. Garcia, MD	5:00 pm 353-355
--	--------------------------	--------------------

354: Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells	Romanos Sklavenitis-Pistofidis, MD	5:15 pm New Orleans Theater C
--	------------------------------------	----------------------------------
